Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2012 May 4;7(3):591–598. doi: 10.1007/s11481-012-9361-4

Fig. 6.

Fig. 6

Activation of CB2 receptor attenuated serum levels of IgE. BALB/c mice were pretreated with Gp1a, a CB2 agonist (Ki=0.037nM) or Gp1a plus SR2 the CB2 antagonist, 18 hrs later the mice were sensitized with OVA/ALUM and boosted with same antigen. Sera were collected at Day 6 after the boosting and ELISAs performed. Treatment with SR2 only had no effect on IgE levels (data not shown). Data bars are serum values from 4–8 mice/group +/− SEM. *=p≤0.05 vs Normal; **=p≤0.05 vs OVA/ALUM and SR2/Gp1a/OVA/ALUM; #=p≤0.05 from OVA/ALUM